Aarvik Therapeutics is focused on advancing cancer treatment through innovative biologics, particularly by leveraging their proprietary antibody platforms. These platforms are designed to enhance the therapeutic index for various oncology targets by integrating modular designs that allow for scalability and versatility in manufacturing. The company is committed to exploring novel molecules that can effectively target multiple mechanisms, thereby offering a promising approach to cancer therapy.

The foundation of Aarvik's technology lies in their THIOMAB platform, which specializes in site-specific antibody-drug conjugation and utilizes common light chain libraries. With over 40 years of combined experience in antibody innovation and drug development, Aarvik aims to address the challenges associated with Antibody Drug Conjugates (ADCs), particularly the high failure rates linked to toxicity. Their strategy includes developing disruptive antibody engineering platforms that create function-blocking antibodies and Immune Cell Engagers (ICEs), focusing on improving both efficacy and safety in cancer treatments.

United States

Aarvik Therapeutics is pursuing exciting, novel molecules with an improved therapeutic index for several oncology targets by combining a novel modular antibody platform with multiple target mechanisms.

Aarvik Therapeutics

Company Details